Novel phosphodiesterase type 5 modulators: a patent survey (2008 – 2010)

Author： Bell Andrew S   Palmer Michael J  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.21, Iss.10, 2011-10, pp. : 1631-1641

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel glucokinase activators: a patent review (2008 – 2010)

By Sarabu Ramakanth   Berthel Steven J   Kester Robert F   Tilley Jefferson W  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 1, 2011-01 ,pp. : 13-33

Informa Healthcare

Access to resources Recommend Favorite

mGlu5 negative allosteric modulators: a patent review (2010 – 2012)

By Emmitte Kyle A  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 4, 2013-04 ,pp. : 393-408

Informa Healthcare

Access to resources Recommend Favorite

5-hydroxytryptamine subtype 6 receptor modulators: a patent survey

By Ivachtchenko Alexandre V   Ivanenkov Yan A   Tkachenko Sergey E  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 9, 2010-09 ,pp. : 1171-1196

Informa Healthcare

Access to resources Recommend Favorite

5-HT2C receptor modulators: a patent survey

By Lee Junwon   Jung Myung Eun   Lee Jinhwa  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 11, 2010-11 ,pp. : 1429-1455

Informa Healthcare

Access to resources Recommend Favorite

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction

By Kendirci Muammer   Bivalacqua Trinity J   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 923-932

Informa Healthcare

Access to resources Recommend Favorite